About enVVeno Medical Corporation - Common Stock (NVNO)
Envveno Medical Corp is a medical technology company focused on developing and commercializing innovative solutions for vascular access procedures. The company specializes in creating cutting-edge products that improve the safety, efficiency, and effectiveness of how healthcare providers access veins for various medical treatments. By leveraging advanced technology and a deep understanding of clinical needs, Envveno aims to enhance patient outcomes and streamline the workflow of healthcare professionals, ultimately contributing to improved care delivery in the vascular access space. Read More
Stay up-to-date with the latest market trends one hour before the close of the markets on Wednesday. Explore the top gainers and losers during today's session in our detailed report.
Let's have a look at what is happening on the US markets in the middle of the day on Wednesday. Below you can find the top gainers and losers in today's session.
As we await the opening of the US market on Wednesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
IRVINE, CA / ACCESS Newswire / August 20, 2025 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that it has received a not-approvable letter from the U.S. Food & Drug Administration (FDA) in response to its Premarket Approval (PMA) application for VenoValve®, a surgical replacement venous valve for treating severe deep chronic venous insufficiency (CVI).
Clinical data and cost-effectiveness analysis demonstrates the VenoValve would provide both better health outcomes and lower costs compared to current standard of care treatments
- enVVeno is developing the VenoValve as a potential treatment option for the approximately 2.5 million patients in the U.S. suffering from severe deep Chronic Venous Insufficiency
Interim two-year follow-up data from 42 subjects in the VenoValve pivotal trial show sustained clinical improvement and continued patient benefit at 24 months compared to baseline
IRVINE, CA / ACCESS Newswire / May 19, 2025 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, announced the appointment of Jennifer Bright as Chief Financial Officer, effective today, May 19, 2025. Ms. Bright brings more than 25 years of financial and strategic leadership experience built across several commercial-stage medical device and pharmaceutical companies including Biolase, Spectrum Pharmaceuticals, Apria Healthcare, Smile Brands, and Teleflex Medical, as well as technical accounting and auditing experience at PricewaterhouseCoopers LLP.
Promising results from the first-in-human study demonstrated that, at three-years post implantation, VenoValve remained safe and effective--achieving a high rate of patency, restoring deep venous competence and maintaining clinical benefits
